mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

Jennie H. Kwon; Mark W. Tenforde; Manjusha Gaglani; H. Keipp Talbot; Adit A. Ginde; Tresa McNeal; Shekhar Ghamande; David J. Douin; Jonathan D. Casey; Nicholas M. Mohr; Anne Zepeski; Nathan I. Shapiro; Kevin W. Gibbs; D. Clark Files; David N. Hager; Arber Shehu; Matthew E. Prekker; Sean D. Caspers; Matthew C. Exline; Mena Botros; Michelle N. Gong; Alex Li; Amira Mohamed; Nicholas J. Johnson; Vasisht Srinivasan; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Akram Khan; Catherine L. Hough; Laurence W. Busse; Abhijit Duggal; Jennifer G. Wilson; Cynthia Perez; Steven Y. Chang; Christopher Mallow; Randal Rovinski; Hilary M. Babcock; Adam S. Lauring; Laura Felley; Natasha Halasa; James D. Chappell; Carlos G. Grijalva; Todd W. Rice; Kelsey N. Womack; Christopher J. Lindsell; Kimberly W. Hart; Adrienne Baughman; Samantha M. Olson; Stephanie Schrag; Miwako Kobayashi; Jennifer R. Verani; Manish M. Patel; Wesley H. Self

doi:10.1093/infdis/jiac118

mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

Jennie H. Kwon, Mark W. Tenforde, Manjusha Gaglani, H. Keipp Talbot, Adit A. Ginde, Tresa McNeal, Shekhar Ghamande, David J. Douin, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Sean D. Caspers, Matthew C. Exline, Mena BotrosMichelle N. Gong, Alex Li, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Akram Khan, Catherine L. Hough, Laurence W. Busse, Abhijit Duggal, Jennifer G. Wilson, Cynthia Perez, Steven Y. Chang, Christopher Mallow, Randal Rovinski, Hilary M. Babcock, Adam S. Lauring, Laura Felley, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, Kelsey N. Womack, Christopher J. Lindsell, Kimberly W. Hart, Adrienne Baughman, Samantha M. Olson, Stephanie Schrag, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel, Wesley H. Self

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Background: The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. Results: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. Conclusions: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

Original language	English (US)
Pages (from-to)	797-807
Number of pages	11
Journal	Journal of Infectious Diseases
Volume	226
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jiac118
State	Published - Sep 1 2022

Keywords

COVID-19
SARS-CoV-2
immunocompromised
solid organ transplantation
vaccine effectiveness

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiac118

Cite this

Kwon, J. H., Tenforde, M. W., Gaglani, M., Talbot, H. K., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Caspers, S. D., Exline, M. C., ... Self, W. H. (2022). mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. Journal of Infectious Diseases, 226(5), 797-807. https://doi.org/10.1093/infdis/jiac118

Kwon, JH, Tenforde, MW, Gaglani, M, Talbot, HK, Ginde, AA, McNeal, T, Ghamande, S, Douin, DJ, Casey, JD, Mohr, NM, Zepeski, A, Shapiro, NI, Gibbs, KW, Files, DC, Hager, DN, Shehu, A, Prekker, ME, Caspers, SD, Exline, MC, Botros, M, Gong, MN, Li, A, Mohamed, A, Johnson, NJ, Srinivasan, V, Steingrub, JS, Peltan, ID, Brown, SM, Martin, ET, Khan, A , Hough, CL, Busse, LW, Duggal, A, Wilson, JG, Perez, C, Chang, SY, Mallow, C, Rovinski, R, Babcock, HM, Lauring, AS, Felley, L, Halasa, N, Chappell, JD, Grijalva, CG, Rice, TW, Womack, KN, Lindsell, CJ, Hart, KW, Baughman, A, Olson, SM, Schrag, S, Kobayashi, M, Verani, JR, Patel, MM & Self, WH 2022, 'mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients', Journal of Infectious Diseases, vol. 226, no. 5, pp. 797-807. https://doi.org/10.1093/infdis/jiac118

@article{d6e40ead6db34f17b2ade255ba194492,

title = "mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients",

abstract = "Background: The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. Results: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. Conclusions: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.",

keywords = "COVID-19, SARS-CoV-2, immunocompromised, solid organ transplantation, vaccine effectiveness",

author = "Kwon, {Jennie H.} and Tenforde, {Mark W.} and Manjusha Gaglani and Talbot, {H. Keipp} and Ginde, {Adit A.} and Tresa McNeal and Shekhar Ghamande and Douin, {David J.} and Casey, {Jonathan D.} and Mohr, {Nicholas M.} and Anne Zepeski and Shapiro, {Nathan I.} and Gibbs, {Kevin W.} and Files, {D. Clark} and Hager, {David N.} and Arber Shehu and Prekker, {Matthew E.} and Caspers, {Sean D.} and Exline, {Matthew C.} and Mena Botros and Gong, {Michelle N.} and Alex Li and Amira Mohamed and Johnson, {Nicholas J.} and Vasisht Srinivasan and Steingrub, {Jay S.} and Peltan, {Ithan D.} and Brown, {Samuel M.} and Martin, {Emily T.} and Akram Khan and Hough, {Catherine L.} and Busse, {Laurence W.} and Abhijit Duggal and Wilson, {Jennifer G.} and Cynthia Perez and Chang, {Steven Y.} and Christopher Mallow and Randal Rovinski and Babcock, {Hilary M.} and Lauring, {Adam S.} and Laura Felley and Natasha Halasa and Chappell, {James D.} and Grijalva, {Carlos G.} and Rice, {Todd W.} and Womack, {Kelsey N.} and Lindsell, {Christopher J.} and Hart, {Kimberly W.} and Adrienne Baughman and Olson, {Samantha M.} and Stephanie Schrag and Miwako Kobayashi and Verani, {Jennifer R.} and Patel, {Manish M.} and Self, {Wesley H.}",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/infdis/jiac118",

language = "English (US)",

volume = "226",

pages = "797--807",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

AU - Kwon, Jennie H.

AU - Tenforde, Mark W.

AU - Gaglani, Manjusha

AU - Talbot, H. Keipp

AU - Ginde, Adit A.

AU - McNeal, Tresa

AU - Ghamande, Shekhar

AU - Douin, David J.

AU - Casey, Jonathan D.

AU - Mohr, Nicholas M.

AU - Zepeski, Anne

AU - Shapiro, Nathan I.

AU - Gibbs, Kevin W.

AU - Files, D. Clark

AU - Hager, David N.

AU - Shehu, Arber

AU - Prekker, Matthew E.

AU - Caspers, Sean D.

AU - Exline, Matthew C.

AU - Botros, Mena

AU - Gong, Michelle N.

AU - Li, Alex

AU - Mohamed, Amira

AU - Johnson, Nicholas J.

AU - Srinivasan, Vasisht

AU - Steingrub, Jay S.

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Martin, Emily T.

AU - Khan, Akram

AU - Hough, Catherine L.

AU - Busse, Laurence W.

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Perez, Cynthia

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Rovinski, Randal

AU - Babcock, Hilary M.

AU - Lauring, Adam S.

AU - Felley, Laura

AU - Halasa, Natasha

AU - Chappell, James D.

AU - Grijalva, Carlos G.

AU - Rice, Todd W.

AU - Womack, Kelsey N.

AU - Lindsell, Christopher J.

AU - Hart, Kimberly W.

AU - Baughman, Adrienne

AU - Olson, Samantha M.

AU - Schrag, Stephanie

AU - Kobayashi, Miwako

AU - Verani, Jennifer R.

AU - Patel, Manish M.

AU - Self, Wesley H.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Background: The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. Results: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. Conclusions: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

AB - Background: The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. Results: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. Conclusions: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

KW - COVID-19

KW - SARS-CoV-2

KW - immunocompromised

KW - solid organ transplantation

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85138448017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138448017&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac118

DO - 10.1093/infdis/jiac118

M3 - Article

C2 - 35385875

AN - SCOPUS:85138448017

SN - 0022-1899

VL - 226

SP - 797

EP - 807

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this